Deep knowledge on 
 small-molecule drugs and 
 the 110,000 global patents 
 covering them 

Free Patent Expiration Alerts


Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

LAMISIL Drug Profile

« Back to Dashboard
Lamisil is a drug marketed by Novartis and Glaxosmithkline Cons and is included in eight NDAs. It is available from four suppliers.

The generic ingredient in LAMISIL is terbinafine. There are twenty-three drug master file entries for this compound. One supplier is listed for this compound. There is one tentative approval for this compound. Additional details are available on the terbinafine profile page.

Summary for Tradename: LAMISIL

Patents:0
Applicants:2
NDAs:8
Suppliers / Packagers: see list4

Pharmacology for Tradename: LAMISIL

Ingredient-typeAllylamine
Drug ClassAllylamine Antifungal

Clinical Trials for: LAMISIL

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis
LAMISIL
terbinafine hydrochloride
TABLET;ORAL020539-001May 10, 1996RXYes<disabled><disabled>
Novartis
LAMISIL
terbinafine hydrochloride
CREAM;TOPICAL020192-001Dec 30, 1992DISCNNo<disabled><disabled>
Novartis
LAMISIL
terbinafine hydrochloride
GRANULE;ORAL022071-001Sep 28, 2007RXNo<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: LAMISIL

These historical archives are available as an add-on to one-year subscriptions.
See the Signup Form for more information.

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis
LAMISIL
terbinafine hydrochloride
TABLET;ORAL020539-001May 10, 19964,680,291<disabled>
Glaxosmithkline Cons
LAMISIL
terbinafine
GEL;TOPICAL020846-001Apr 29, 19986,005,001*PED<disabled>
Glaxosmithkline Cons
LAMISIL
terbinafine
GEL;TOPICAL020846-001Apr 29, 19986,121,314*PED<disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2016 thinkBiotech LLC
ISSN: 2162-2639

Connect with Social Media:

`abc